Kevin Church, CHIEF SCIENTIFIC OFFICER at Athira Pharma, Inc. (ATHA), sold 876 shares at $6.88 ($6K) on 2026-01-02, disclosed to the SEC on 2026-01-05.
Seasonal sale ($6k) by CHIEF SCIENTIFIC OFFICER — this insider has traded ATHA in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| ATHA | SELL | 2025-01-03 | $5K | — | Filing → |
| ATHA | SELL | 2024-09-05 | $1K | — | Filing → |
| ATHA | SELL | 2024-02-16 | $7K | — | Filing → |